Background/Objectives: Despite widespread use of low-density lipoprotein cholesterol (LDL-C)-lowering therapies, substantial residual atherosclerotic cardiovascular disease (ASCVD) risk persists in primary care populations. Lipoprotein(a) [Lp(a)] is a common, genetically determined lipoprotein and is not routinely measured on standard lipid panels. Unlike LDL, Lp(a) contains an apolipoprotein(a) moiety with unique biological properties, including oxidized phospholipid transport, pro-inflammatory vascular signaling, and antifibrinolytic effects. This narrative literature review examines the hypothesis that Lp(a) represents a distinct, causal atherogenic lipoprotein with ASCVD risk independent of apolipoprotein B (apoB) and systemic inflammation. This review draws from cardiovascular prevention and risk stratification literature. No human subjects were involved.
Methods: Targeted searches of PubMed and major cardiovascular and lipidology journals were performed to identify English-language peer-reviewed studies published from 2000-2026 examining Lp(a) biology and cardiovascular outcomes. Representative search terms included combinations of lipoprotein(a) or Lp(a) with atherosclerotic cardiovascular disease, coronary heart disease, stroke, apoB, LDL cholesterol, and C-reactive protein. Titles and abstracts were screened for relevance, followed by full-text review of potentially eligible articles. Included sources comprised Mendelian randomization studies, large prospective cohorts, randomized trial sub-analyses, and high-quality reviews; small case series and non-peer-reviewed reports were excluded. Study relevance was assessed based on sample size, adjustment for major confounders, and consistency of findings across populations. Measurement techniques included immunoassays for Lp(a) and apoB, enzymatic assays for LDL-C, and high-sensitivity C-reactive protein (hsCRP) assays. Results were derived from adjusted analyses accounting for key confounders, including age, sex, cardiometabolic comorbidities, smoking status, and lipid-lowering therapies; no formal meta-analysis was performed. Primary outcomes assessed associations between elevated Lp(a) and ASCVD outcomes independent of LDL-C, apoB, and inflammation, with supporting mechanistic measures of vascular dysfunction and thrombosis.
Discussion/Results: This review identifies Lp(a) as an under-recognized source of inherited cardiovascular risk in family medicine. Limitations include reliance on published data and heterogeneous study designs. Increased awareness of Lp(a) is directly relevant to primary care risk assessment. Elevated Lp(a) is causally associated with ASCVD independent of LDL-C, apoB, and hsCRP, with greater per-particle atherogenicity and mechanistic links to endothelial dysfunction and thrombosis.
Conclusions: Lp(a) is a causal, apoB-independent driver of residual ASCVD risk. Incorporating Lp(a) testing into primary practice may improve cardiovascular risk strat
Methods: Targeted searches of PubMed and major cardiovascular and lipidology journals were performed to identify English-language peer-reviewed studies published from 2000-2026 examining Lp(a) biology and cardiovascular outcomes. Representative search terms included combinations of lipoprotein(a) or Lp(a) with atherosclerotic cardiovascular disease, coronary heart disease, stroke, apoB, LDL cholesterol, and C-reactive protein. Titles and abstracts were screened for relevance, followed by full-text review of potentially eligible articles. Included sources comprised Mendelian randomization studies, large prospective cohorts, randomized trial sub-analyses, and high-quality reviews; small case series and non-peer-reviewed reports were excluded. Study relevance was assessed based on sample size, adjustment for major confounders, and consistency of findings across populations. Measurement techniques included immunoassays for Lp(a) and apoB, enzymatic assays for LDL-C, and high-sensitivity C-reactive protein (hsCRP) assays. Results were derived from adjusted analyses accounting for key confounders, including age, sex, cardiometabolic comorbidities, smoking status, and lipid-lowering therapies; no formal meta-analysis was performed. Primary outcomes assessed associations between elevated Lp(a) and ASCVD outcomes independent of LDL-C, apoB, and inflammation, with supporting mechanistic measures of vascular dysfunction and thrombosis.
Discussion/Results: This review identifies Lp(a) as an under-recognized source of inherited cardiovascular risk in family medicine. Limitations include reliance on published data and heterogeneous study designs. Increased awareness of Lp(a) is directly relevant to primary care risk assessment. Elevated Lp(a) is causally associated with ASCVD independent of LDL-C, apoB, and hsCRP, with greater per-particle atherogenicity and mechanistic links to endothelial dysfunction and thrombosis.
Conclusions: Lp(a) is a causal, apoB-independent driver of residual ASCVD risk. Incorporating Lp(a) testing into primary practice may improve cardiovascular risk strat